Tresca is a writer and speaker who covers digestive conditions, including IBD. She was diagnosed with ulcerative colitis at age 16. Suzanne Fisher, RD, is a registered dietitian and licensed ...

Researchers at Peter MacCallum Cancer Centre have developed a digital phenotype to assist with automatically identifying ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — Abivax on Monday night ...

Abivax said on Monday its experimental ulcerative ​colitis drug helped harder-to-treat groups of patients achieve remission, sending ‌U.S.-listed shares of the Paris-based company soaring 26.4% in ...

Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score = 20 and key ...

If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitiligo, addressing important treatment needs for those living with the chronic, unpredictabl ...

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of children six years of age and older with ...

In patients with ulcerative colitis exposed to anti-TNF therapy, tofacitinib is linked to higher rates of clinical and ...

News and commentary from the world of gastroenterology and hepatology ...

Among biologic-naive patients with moderate to severe ulcerative colitis, upadacitinib and infliximab had the quickest onset ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved SKYRIZI® (risankizumab) for the treatment of children ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...